GlassScriptPhysician profile
John V Earnhart
NPI 1043218084
$10,277.83
in general payments reported to CMS, 2019-2025
47 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $267 · 2021: $1,615 · 2022: $2,352 · 2023: $1,948 · 2024: $1,544 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,015.96 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $827.36 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $534.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $406.51 | 2019-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $397.66 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.94 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $343.05 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $303.83 | 2019-2022 | |
| Pfizer INC. | $272.63 | 2019-2025 | |
| Amarin Pharma, INC. | $253.20 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $243.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $220.00 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $176.72 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $163.13 | 2021-2025 | |
| Daiichi Sankyo INC. | $138.60 | 2019-2024 | Injectafer |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Earnhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.